These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. Mato AR; Ghosh N; Schuster SJ; Lamanna N; Pagel JM; Flinn IW; Barrientos JC; Rai KR; Reeves JA; Cheson BD; Barr PM; Kambhampati S; Lansigan F; Pu JJ; Skarbnik AP; Roeker L; Fonseca GA; Sitlinger A; Hamadeh IS; Dorsey C; LaRatta N; Weissbrot H; Luning Prak ET; Tsao P; Paskalis D; Sportelli P; Miskin HP; Weiss MS; Svoboda J; Brander DM Blood; 2021 May; 137(20):2817-2826. PubMed ID: 33259589 [TBL] [Abstract][Full Text] [Related]
9. Images in Vascular Medicine. Rumpel-Leede phenomenon in a patient with chronic lymphocytic leukemia treated with acalabrutinib. Bossory Goike L; Dean S Vasc Med; 2020 Jun; 25(3):281-282. PubMed ID: 32146868 [No Abstract] [Full Text] [Related]
10. Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy. Taneja A; Jones J; Pittaluga S; Maric I; Farooqui M; Ahn IE; Wiestner A; Sun C Leuk Lymphoma; 2019 Feb; 60(2):519-522. PubMed ID: 29978754 [No Abstract] [Full Text] [Related]
11. [Research Progress of Targeted Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma --Review]. Chen D; Wang MY; Tian C Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880 [TBL] [Abstract][Full Text] [Related]
12. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Cervantes-Gomez F; Kumar Patel V; Bose P; Keating MJ; Gandhi V Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052 [No Abstract] [Full Text] [Related]
13. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251 [TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328 [TBL] [Abstract][Full Text] [Related]
15. Second generation BTK inhibitors impair the anti-fungal response of macrophages and neutrophils. Colado A; Marín Franco JL; Elías EE; Amondarain M; Vergara Rubio M; Sarapura Martínez V; Cordini G; Fuentes F; Balboa L; Fernandez Grecco H; Pavlovsky M; Bezares F; Morande P; Giordano M; Gamberale R; Borge M Am J Hematol; 2020 Jul; 95(7):E174-E178. PubMed ID: 32267009 [No Abstract] [Full Text] [Related]
16. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia. Woyach JA Clin Adv Hematol Oncol; 2021 Jul; 19(7):436-438. PubMed ID: 34236341 [No Abstract] [Full Text] [Related]
17. The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia. Gianfelici V; Levato L; Molica S Curr Hematol Malig Rep; 2020 Aug; 15(4):343-349. PubMed ID: 32500413 [TBL] [Abstract][Full Text] [Related]
18. BTK/PD-1 blockade for treatment of Richter's transformation. Tang PS; Tam CS Lancet Haematol; 2019 Feb; 6(2):e59-e60. PubMed ID: 30642820 [No Abstract] [Full Text] [Related]